Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 412

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 412
---
| Share capital            | Nominal value of subscribed share capital                                                                                                                                                            |
| Share premium            | Amount subscribed for share capital in excess of nominal value.                                                                                                                                      |
| Merger reserve           | Represents the difference between the fair value and nominal value of shares issued on the acquisition of subsidiary companies where the Company has elected to take advantage of merger accounting. |
| Foreign exchange reserve | Gains/losses arising on retranslating the net assets of overseas operations into sterling                                                                                                            |
| Warrant reserve          | Represents the following:                                                                                                                                                                            
 ·     the                                                                                                                                                                                            
 fair value of warrants denominated in £ at the date of grant. The number and price are fixed at the date of grant. The warrants                                                                      
 expire in November 2025                                                                                                                                                                              
 ·     the                                                                                                                                                                                            
 fair value of pre-funded warrants granted. The pre-funded warrants do not have an expiry date.                                                                                                       
 ·     The                                                                                                                                                                                            
 fair value of Series A, B and C warrants denominated in US$ at the date of grant but allow for the warrants to be exercised on an alternative                                                        
 cashless basis effectively allowing the holders to exercise for nil consideration.                                                                                                                   |
| Accumulated deficit      | All other net gains and losses and transactions with owners (e.g., dividends) not recognised elsewhere.                                                                                              |

| 23 | Retirement benefits |

The Group operates a
defined contribution pension scheme for the benefit of its employees. The assets of the scheme are administered by trustees in funds independent
from those of the Group. The annual charge for the year was £86,000 (2022: £98,000)

| F-71 |

| 24 | Share-based payments |

Share Options

The Group has issued
options over ordinary shares under the 2014 Biodexa Pharmaceuticals PLC Enterprise Management Incentive Scheme and unapproved share options
awarded to non-UK staff. In addition, certain share options originally issued over shares in Biodexa Limited under the Biodexa Limited
2008 unapproved share option scheme or Biodexa Limited 2013 approved Enterprise Incentive scheme were reissued in 2015 over shares in
Biodexa Pharmaceuticals PLC under the 2014 Biodexa Pharmaceuticals PLC Enterprise Management Incentive Scheme. Exercise of an option is
subject to continued employment.

At a General Meeting
on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result